Treated with Venetoclax with rituximab for rel... - CLL Support

CLL Support

23,088 members39,651 posts

Treated with Venetoclax with rituximab for relapsed or refractory CLL then Bloodwise need help for the NICE appraisal on 22 Jun.

Myrddin profile image
0 Replies

There is a health technology appraisal request that Bloodwise need help with. The request is for a NICE appraisal of venetoclax in combination with rituximab for treating relapsed or refractory CLL.

Ideally, we are looking for someone who has had the treatment. However if you haven’t, but still have insight into this treatment, it would be hugely helpful to speak with you about it.

If this is something that applies to you or would be happy/interested to help with, please could you get in touch with our Policy Officer Charlotte Cherry on ccherry@bloodwise.org.uk ASAP.

The deadline for the NICE submission is June 22nd- short notice - I apologise -however we feel that it will have a large impact on CLL so would be great if you can help!

Message to Bloodwise Ambassadors from

Grace Harington

Volunteer and Ambassador Coordinator

T: 020 7504 2238

E: gharington@bloodwise.org.uk

W: bloodwise.org.uk

Written by
Myrddin profile image
Myrddin
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Scottish Medicines Consortium approves Venetoclax + Rituximab Treatment for relapsed/refractory CLL

Venetoclax has been approved by the Scottish Medicines Consortium (SMC) for treating adults with...

UK Patients: Can you help with your opinion about treatment options. Have you received Ibrutinib + Venetoclax as your first treatment?

Can you help us to provide evidence of the patient experience of treatments in CLL and...

CLL 17p - Rituximab/Imbruvica then Rituximab/Venetoclax or enter in a clinical trial ?

First of all I would like to thank you for responding to my previous post... It really helps me !...

10 year survival with CLL, treated or not, comes with significant risk for other cancers

http://newsmail.wyanokegroup.com/trk/clickp?ref=zs171oic4_1-e4dex318364x01777&ecp=B45B94CF-36EA-E511

Opportunity to support the listing of Acalabrutinib and Venetoclax for the treatment of Australians with CLL

No matter where you live, you can support the access of Australians with CLL to Acalabrutinib or...